Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study. (Q52493872)

2 May 2018

title

Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study. (English)

1 reference

2 May 2018

1 reference

2

P W Wilson

1 reference

2 May 2018

author name string

D Levy

series ordinal

1

1 reference

2 May 2018

K M Anderson

series ordinal

3

1 reference

2 May 2018

W P Castelli

series ordinal

4

1 reference

2 May 2018

language of work or name

English

0 references

publication date

1 March 1990

1 reference

2 May 2018

published in

American Heart Journal

1 reference

2 May 2018

volume

119

1 reference

2 May 2018

issue

3 Pt 2

1 reference

2 May 2018

page(s)

712-7; discussion 717

1 reference

2 May 2018

Epidemiological approaches to heart disease: the Framingham Study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

Cardiovascular risk factors in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

The filter cigarette and coronary heart disease: the Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

Cardiovascular risks: New insights from Framingham

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

A multivariate analysis of the risk of coronary heart disease in Framingham

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

Coronary risk prediction in adults (the Framingham Heart Study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2805%2980050-X

10.1016/S0002-8703(05)80050-X

7 January 2021

Identifiers

DOI

1 reference

2 May 2018

1 reference

2 May 2018